The US Food and Drug Administration (FDA) has approved a supplement to Aethlon Medical’s existing investigational device exemption (IDE) for its Hemopurifier device in viral disease.

The approvals enable the testing of the Hemopurifier in patients with SARS-CoV-2/Covid-19 in a new feasibility study.

Hemopurifier is a clinical-stage device designed to fight cancer and life-threatening viral infections. It is an FDA designated breakthrough device to treat life-threatening viruses that are not addressed with approved therapies.

Aethlon Medical said the feasibility study is the device equivalent of a phase 1 trial and will enrol up to 40 subjects at approximately 20 centres in the US with established laboratory diagnosis of Covid-19.

Other criteria for subjects include being admitted to an intensive care unit and having acute lung injury and / or severe or life-threatening disease.

Aethlon Medical CEO Timothy Rodell said: “We believe that the Hemopurifier may have the potential to help severely affected patients with Covid-19. We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Hemopurifier device has earlier been tested in patients with hepatitis C virus infection and in a patient with Ebola virus infection. The device has not yet received FDA approval for any indication.

A laboratory version of the Hemopurifier has been demonstrated to clear several other viruses in Vitor, including a model version of the Middle Eastern Respiratory Syndrome (MERS) virus.

MERS virus is a coronavirus from the same family as the SARS-CoV-2 virus that causes Covid-19.